Navigation Links
Scientists can predict nano drug outcome
Date:2/5/2009

Scientists including one from The University of Texas Health Science Center at Houston successfully predicted the outcome of a nano drug on breast tumors in a pre-clinical study. Their research could help determine which patients will respond best to cancer-fighting nano drugs.

Researchers from the Georgia Institute of Technology and Emory University also participated in the study, which appears in the February issue of Radiology.

The investigators used contrast agents encapsulated in tiny fat bubbles called liposomes to determine if breast tumors in rodents could be breached by liposomes loaded with a cancer drug called liposomal doxorubicin. The liposomes were administered intravenously.

When scientists X-rayed the rodents, the investigators received good images of porous breast tumors which had absorbed the contrast agents. On the other hand, poor images indicated the contrast agents had not substantially penetrated the tumor. When liposomal doxorubicin was administered, it was associated with better therapeutic results in the tumors with superior images.

"We can tell if the animals are candidates for the treatment or not," said Ananth Annapragada Ph.D., one of two senior authors and an associate professor at The University of Texas School of Health Information Sciences at Houston.

Higher uptake of the probe by the tumor, indicating leakier vasculature, was associated with a slower tumor growth rate, suggesting a better therapeutic outcome with liposomal doxorubicin, the authors wrote. A nanometer is a billionth of a meter and a liposome is about 100 nanometers.

Nano drugs for cancer like liposomal doxorubicin are designed to increase the amount of drug reaching tumors. Currently, when an intravenous cancer drug is administered, very little reaches its intended target. The remaining drug circulates in the bloodstream and can cause side effects.

Liposomes carrying drugs infiltrate leaky
'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3042
University of Texas Health Science Center at Houston
Source:Eurekalert

Page: 1 2

Related biology news :

1. CSHL scientists discover how companion cells to sperm protect them from genetic damage
2. Weizmann Institute scientists show extra copies of a gene carry extra risk
3. Scientists discover how deadly fungus protects itself
4. Scientists discover hot spot for toxic HABS off Washington coastline
5. Scientists uncover new class of non-protein coding genes in mammals with key functions
6. Smithsonian scientists receive coveted BBVA Ecology and Conservation Award
7. CSHL scientists clarify editing error underlying genetic neurodegenerative disease
8. Weizmann Institute scientists discover how cancer cells survive a chemotherapy drug
9. Substantial work ahead for water issues, say scientists at ACS Final Report briefing
10. CSHL scientists find a new class of small RNAs and define its function
11. Scientists uncover new genetic variations linked to psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... (hNoV), also known as the winter vomiting bug, is one ... virus is highly contagious, causing vomiting and diarrhea, and the ... cure; sufferers have to let the virus run its course ... is frequently associated with outbreaks of hNoV but it remains ...
... The human skin is home to countless microorganisms that we ... Our invisible passengers known as the skin microbiome - ... immune system, protecting us from pathogens, and mediating skin disorders. ... is transmitted between players in a contact sport, using roller ...
... in French . Researchers at the University ... discovered a new mechanism that allows some cells in our body ... by Roman soldiers depicted in the Asterix series. Collective cell migration ... but it is also used by cancerous cells to disseminate efficiently ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced ... in Germany to initiate its planned Phase II ... with low-grade cervical lesions.The clinical study was designed, ... on the absorption and elimination profile of Topical ...
... Percent of Outstanding Indevus Shares Have Been Accepted ... Pharmaceuticals (Nasdaq: ENDP ) announced today ... time, on March 13, 2009, approximately 71,008,964 shares ... were validly tendered and accepted for purchase in ...
... PortfolioNEW YORK, March 16 Samtheo Biopharma LLC ... subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, ... that selectively inhibits the activation of all three ... pathway has been found to play an important ...
Cached Biology Technology:Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: